Nexstim Plc: Shares subscribed for in the directed share issue have been registered


Helsinki, Finland: 18 November 2019 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) announced on 15 November 2019 that an aggregate of 15,687,350 new shares of Nexstim were subscribed for in the directed share issue. Such new shares have today been registered with the Trade Register.

Pursuant to the registration of the shares issued in the directed share issue with the Trade Register, the number of shares in the company is 61,599,912.

The trading of the new shares registered will begin approximately on 19 November 2019 in Nasdaq First North Growth Market Finland and approximately on 20 November 2019 in Nasdaq First North Growth Market Sweden.

More info on Nexstim‘s website.

Categories: News


Apax Funds launch GamaLife with GNB Vida acquisition


London and Lisbon, 14 October 2019: GamaLife, a new European life and wealth consolidation platform, launches today with the acquisition of GNB – Companhia de Seguros de Vida, S.A. (“GNB Vida”) from Novo Banco Group (“Novo Banco”) in Portugal.

GamaLife, backed by funds advised by Apax Partners, intends to build on its acquisition of GNB Vida as the start of a wider consolidation strategy in the life insurance market. Led by Matteo Castelvetri, Group CEO, GamaLife was set up with a view to transform traditional life insurance companies via a forward-thinking approach whereby technological innovation and focus on both transparency and service take a primary role. GamaLife’s acquisition strategy will focus on businesses with high turnaround potential and ability to benefit from cross-border best practices, whilst keeping central functions nimble.

Headquartered in Lisbon, GNB Vida offers protection, savings and retirement products distributed through Novo Banco’s 401 branches. The transaction will see GamaLife relaunch the product and distribution offering of GNB Vida with a view to becoming a true leader in the Portuguese insurance market thanks to a new long-term exclusive distribution agreement with Novo Banco. In doing so, GNB Vida will look to accelerate new product focus, in turn developing innovative solutions for the benefit of its end customers. GNB Vida is delighted to continue its relationship with Novo Banco and partner on this trajectory of accelerated growth.

Mr. Castelvetri said: “We are excited to launch GamaLife and believe Apax are an excellent partner to help us create an innovating pan-European life and wealth platform. We are delighted to complete our first acquisition in GNB Vida and enter the fast-growing Portuguese market. We believe that the combination of Novo Banco’s strong franchise and market position, together with our focus on new products and solutions, will bring substantial benefits to Novo Banco’s 1.3 million customers.”

Frank Ehmer, Partner at Apax Partners, said: “We have been proactively targeting the life insurance and wealth management markets for a number of years. We are excited to back Matteo and his team to grow the GamaLife platform, both organically and through further consolidation of the European market. In doing so, we are pleased to have the opportunity to help cement GNB Vida’s position as a market-leading life insurance partner for Novo Banco.”

About GamaLife

GamaLife is a pan-European life and wealth management platform founded in 2019 and focused on technology and sustainability. GNB Vida, which is regulated by the Autoridade de Supervisão de Seguros e Fundos de Pensões, held total assets of EUR 5.1 billion and total equity of EUR 391 million as of June 2019. For more information see:

About Apax Partners

Apax is a leading global private equity advisory firm. Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.USD 50 billion. The Apax Funds invest in companies across four global sectors of Tech & Telco, Services, Healthcare and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see:

Media Contacts: 

For Apax Partners

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 |

USA Media: Todd Fogarty, Kekst CNC | +1 212-521-4854 |

UK Media: James Madsen / Matthew Goodman, Greenbrook | +44 20 7952 2000 |

Categories: News


Apax Funds and consortium partners complete sale of Acelity to 3M for $6.725 billion


Completion of transaction marks end of highly successful collaboration with management team to transform Acelity into a global medical device leader

San Antonio and New York, October 11, 2019: Funds advised by Apax Partners together with consortium partners Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, today announced the completion of the sale of Acelity and its KCI subsidiaries to 3M for $6.725 billion.

Apax Funds and consortium partners complete sale of Acelity to 3M for $6.725 billion

Since 2011, Apax and its consortium partners worked to reshape Acelity from a loose collection of businesses into a focused global leader. This was achieved through a strategic M&A program which included targeted acquisitions as well as the disposals of non-core businesses. In addition, a range of activities were undertaken to accelerate organic growth, including investments in R&D, medical education, clinical studies, and the expansion of its sales force. The result of these initiatives transformed Acelity into the world’s largest wound care company focused on advanced wound care, including negative pressure wound therapy.

Steven Dyson and Arthur Brothag, Partners at Apax Partners, said, “We are proud of our work with Acelity and our consortium partners. In many ways, this transaction represents what Apax seeks to achieve: namely, developing a high conviction thesis through sub-sector insights, forming a strong partnership with a talented management team, and working together to transform a business to become the global leader in its space. We wish Acelity well and look forward to watching the company continue to thrive under new ownership.”

R. Andrew Eckert, CEO of Acelity during the ownership of the Apax Funds and its consortium partners, said: “It has been a pleasure to work with Apax and its consortium partners. They have demonstrated a very strong understanding of our space and helped us reshape our business and invest to capture significant growth. It’s incredibly fulfilling to reflect on the rapid expansion in innovation and new products Acelity has delivered to the marketplace in this time. I especially want to recognize the Acelity workforce for their dedication to improving patients’ lives worldwide in bringing these new therapies forward.”

About Apax Partners

Apax Partners is a leading global private equity advisory firm. Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.$50 billion. The Apax Funds invest in companies across four global sectors of Healthcare, Tech & Telco, Services, and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see:

In Healthcare, the Apax Funds have invested c.$8 billion of equity across medical devices, pharmaceuticals, healthcare services and healthcare IT. Within the medical devices sub-sector, the Apax Healthcare team has partnered with a variety of businesses such as Mӧlnlycke, Vyaire Medical, Candela and Healthium to create strategic leaders in their space.

Media Contacts

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 |

USA Media: Todd Fogarty, Kekst CNC | +1 212-521 4854 |

UK Media: Matthew Goodman, Greenbrook | +44 20 7952 2000 |

Notes to Editors

London-headquartered Apax Partners (, and Paris-headquartered Apax Partners ( had a shared history but are separate, independent private equity firms.

Categories: News


Baird Capital and Council Capital Exit emids

Baird Capital

Baird Capital and Council Capital Exit emids

NASHVILLE, TN – September 26, 2019Council Capital, a healthcare-focused private equity firm based in Nashville, and Baird Capital, the direct private investment arm of Baird based in Chicago, announced today that they have sold their stakes in emids to New Mountain Capital. Terms of the transaction were not disclosed. Both firms initially invested in emids in 2013.

emids is a global provider of technology services and solutions for healthcare payers and providers. The company’s services include consulting, custom application development, and data solutions that support EHR application deployment and management, analytics, data integration and governance, software development and testing, and business intelligence. emids is headquartered in Nashville.

Since 2013, emids has grown exponentially by expanding its offerings, growing its customer base, and acquiring Encore Health, which expanded its coverage in the provider market. emids’ success has been reinforced by its outstanding team, who are responsible for emids consistently achieving strong KLAS ratings – the standard for assessing vendor quality in the healthcare market.

“We sincerely enjoyed partnering with the team at emids and are excited for the company to continue its growth,” said Grant Jackson, Managing General Partner at Council Capital. “emids is well positioned to continue to capitalize on the tremendous opportunities within the healthcare information technology services sector, and we are confident that the company will continue to thrive in partnership with New Mountain Capital.”

“We consider ourselves fortunate to have worked with emids and its talented leadership team over the last six years,” said Jim Pavlik, Partner at Baird Capital. “We are proud of emids’ growth and leadership in enabling digital transformation in the healthcare industry and are excited about the company’s opportunity to drive further innovation and value for its clients in its next phase of growth.”

Saurabh Sinha, Founder and CEO of emids, added, “We have appreciated our partnership with Council Capital and Baird Capital over the last six years. Fast-growing companies don’t have trouble accessing capital. What I needed was access to proven company builders who share best practices, open doors to fuel growth and are people I trust to have the company’s best interests at heart. Both Council and Baird delivered on this for us.”

About Baird Capital

Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 300 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. Incorporated. For more information, please visit

About Council Capital

Council Capital is a healthcare-focused private equity firm based in Nashville, Tennessee. Council Capital invests in lower middle market healthcare-related companies where it can drive growth by applying its Council Model, which draws upon the resources and experience of its CEO Council (experienced industry executives), Strategic Healthcare Investors, and Shared Portfolio Executives. Council Capital leverages its Council Model to attract and support leading management teams and portfolio companies on the ‘right side’ of change in the healthcare industry – where growth will accelerate as cost pressure and quality demands increase. Council Capital targets control and minority investments with enterprise values between $10 million and $50 million. For more details, please visit

About emids

emids is a global provider of healthcare technology expertise and consulting services and solutions that serves payers, providers and tech enablers. Headquartered in Nashville, emids helps bridge the critical gaps in accessible, affordable, high-quality healthcare by providing advisory consulting services, custom application development and data solutions. Services include EHR application deployment and management, analytics, data integration and governance, software development and testing, and business intelligence. Visit

Baird Capital


Categories: News


Dyne Therapeutics announces appointment of Joshua Brumm as President and Chief Executive Office


in portfolio news

Industry veteran brings extensive experience leading biotech companies through periods of growth.

WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer.

“Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.”

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.”
“On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.”

Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

About Dyne Therapeutics
Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass.

For more information, please visit
Media Contact Ten Bridge Communications Max Stendahl, 508-277-8117

Categories: Personalia


Mainstay Medical announces acceptance for filing by US FDA of Pre-Market Approval (PMA) Application for ReActiv8


Dublin, Ireland: 1 October 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth of Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, today announces that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Pre-Market Approval (PMA) application for ReActiv8.

Mainstay submitted the PMA to the FDA in August. Per regulation, the FDA will notify the applicant whether the PMA has been accepted for filing within 45 days after submission. By accepting the Company’s PMA for filing, the FDA has made a threshold determination that the application is sufficiently complete to begin an in-depth review. Mainstay continues to expect a decision on approval around the end of 2020.

More information on Mainstay’s website.


Categories: News


NPM Capital acquires Zorgwerk from ADG dienstengroep

NPM Capital

ADG dienstengroep and NPM Capital announced today that they have reached agreement on NPM Capital’s acquisition of Zorgwerk. The proposed takeover will be submitted for approval to the competent authorities and is expected to be completed by the end of this year. 

Zorgwerk is the market leader in the Netherlands in staffing services for healthcare, social assistance and child care. The strength of the company lies in the digital transformation that Zorgwerk already has initiated back in 2005, which involved creating a fully online platform used on a daily basis by thousands of healthcare professionals across the Netherlands. This platform enables Zorgwerk to match the supply of and demand for healthcare professionals efficiently and effectively. This involves short-term services (including emergency services) provided daily by organisations operating in a variety of sectors (including nursing and care, home care, healthcare and mental health care). Care professionals favour Zorgwerk because the platform provides them with the flexibility and empowerment they need. This is consistent with the public demand among care professionals for greater independence.

Driving further growth

Johan Terpstra, Managing Director of NPM Capital: “We are very excited to be given this opportunity to invest in Zorgwerk. The management, led by CEO Daniëlle van der Burg, were able to successfully digitise their business model, giving them a head-start we would like to build on further. We will be giving the team the freedom and opportunity to achieve their goals and further grow the company. We believe that, in partnering with the Zorgwerk team, we will do an even better job of matching the supply of and demand for care workers using digital resources and will provide improved services to care institutions in a variety of sectors through temporary and well-qualified care workers.”

Hans Kroeze, CEO of ADG dienstengroep: “Zorgwerk has gone from strength to strength in recent years operating under the auspices of ADG. It substantially increased its client base, revenue and profit, while at the same time contributing to ADG’s further growth. I firmly believe that Zorgwerk’s strategy will continue to thrive – and may be accelerated where necessary – with NPM Capital as its new shareholder.”

Daniëlle van der Burg, who will remain Zorgwerk’s CEO once the acquisition is completed, is looking forward to working with NPM: “In NPM Capital, we have found a strong partner that supports our growth objectives. Our employees and clients are central to our culture, with the main goal being innovating and improving our business processes. It is this combination to which we owe our leading position and excellent reputation in temporary staffing solutions for providers of care services. With NPM as our new owner, I see great potential for further improving our strategy and accelerating our growth.”

The acquisition of Zorgwerk will not affect any jobs: all staff will remain employed by Zorgwerk, while Daniëlle van der Burg will continue to serve as CEO.

Categories: News


Navamedic Q2 2019 – growth continues and separate listing of Medtech division


The growth continues for Navamedic and the company reported revenues of NOK 47.2 million in the second quarter of 2019, up 4.4% from the same period in 2018. The demerger and separate listing of the Medtech division has been approved and is expected to be completed in the beginning of November 2019. The demerger is expected to provide a platform for accelerated growth in both Pharma and Medtech.

Navamedic reported revenues of NOK 47.2 million in the second quarter of 2019, up from NOK 45.2 million in the corresponding quarter last year. The gross margin was 34.4% (34.9% in Q2 2018). The EBITDA came in at NOK 0.9 million (MNOK 5.6 in Q2 2018), mainly due to project costs related to the demerger of Medtech and increased focus on business development.

In the first half of 2019, revenues increased to NOK 92.7 million (MNOK 87.8 in Q1 2018), while EBITDA came in at NOK 1.4 million (MNOK 2.7 in Q1 2018).

“We have initiated the implementation of the new growth strategy and see a great potential in leveraging Navamedic’s highly scalable pharma market access platform. In the second quarter of 2019, we continued to deliver growth driven by the strong momentum in our Obesity and Medical Nutrition product categories. We are looking forward to continue to drive growth in our current product portfolio, in addition to introducing new products and explore the arising M&A opportunities,” says Kathrine Gamborg Andreassen, CEO of Navamedic.

Gamborg Andreassen further adds; “As we continued to build on our core business to provide a highly efficient market access platform for pharma companies, we also proposed a key strategic decision to the Extraordinary General Meeting: demerger and separate listing of the Medtech division, to provide a platform for accelerated growth in both Pharma and Medtech.”

The Extraordinary General Meeting of Navamedic approved the plan for demerger and separate listing of the Medtech division. The Medtech divison is commercialising Sippi®, a new system for digital, wireless, urine measurement, in global markets. The proprietary Sippi® technology represents significant long -term revenue opportunities for Navamedic.

“Urine measurement is the last entrenchment of manual measurement at the intensive care units. Today, urine measurement is binding healthcare personnel’s time and resources, resulting in stress and mistakes, and ultimately hospital acquired infections. As the next generation digital, wireless, urine measurement and infection prevention system, Sippi® is approaching attractive markets with a unique product which meets a significant medical need. We see significant long -term global market opportunities for the proprietary Sippi® product family ahead,” says Gamborg Andreassen, CEO of Navamedic.

See 2H 2019 report at the company webpage

Categories: News


iSTAR Medical announces EUR 40.1 million financing round lead by Gimv to support further development of an innovative glaucoma treatment


iSTAR Medical SA, a Wavre-based private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announces the completion of a EUR 40.1 million Series C financing. The financing was led by Gimv and LSP (Life Sciences Partners), with participation by Earlybird and BNP Paribas Private Equity. Gimv will invest EUR 10 million in total. Existing shareholders including Capricorn Partners, Walloon Region Investment Fund (SRIW) and Belgian Federal Investment Fund (SFPI‐FPIM) also participated. This financing will support iSTAR Medical’s development towards commercialisation of its MINIject device in Europe and US.

iSTAR Medical ( was founded in 2011 and is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally affecting more than 92 million people worldwide and driven by an increase in intraocular pressure. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma. iSTAR Medical’s MINIject, an ab-interno MIGS implant, provides a powerful and reliable solution to safely reduce intraocular pressure (IOP) by enhancing aqueous humour outflow from the anterior chamber to the supraciliary space, and has been designed to be a best-in-class MIGS device. Unlike other technologies, MINIject uses the innovative STAR® material, a soft and flexible, medical-grade silicone with a micro-porous, multi-channel geometry.

Bram Vanparys, Partner in Gimv’s Health & Care team, says: “We are looking forward to help building iSTAR Medical to become the leading player in the MIGS field. With the support and expertise of a solid specialized Life Science syndicate, iSTAR Medical now has all the tools to leverage and expand the excellent clinical results of the MINIject. We look forward to support the company in its further development of the MINIject in Europe and the upcoming US pivotal trial.”

This investment marks Gimv’s continued activity in the life sciences sector. With the recent successful exit of Breath Therapeutics and the substantial capital raise in AgroSavfe, the Health & Care platform is committed to further expand the life sciences portfolio.

For more information on this transaction, we refer to the press release of iSTAR Medical in attachment.

Read all press releases

Categories: News


Advarra Announces Intent to Acquire Forte, Market-Leading Provider of Clinical Technology Solutions

The move strengthens the site-centric solutions portfolio of the largest global research compliance services organization

COLUMBIA, Md. and MADISON, Wis., September 5, 2019Advarra, the premier provider of institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services, is pleased to announce the intent to acquire Forte, the industry’s leading provider of standards-based clinical research technology solutions for major academic medical centers, cancer centers, and health systems. Forte offers a fully integrated suite of solutions for clinical trial management, clinical data management, and research administration, including OnCore, Forte’s flagship enterprise CTMS.

“Forte is known across the research community as the gold standard for eClinical technology solutions,” said Pat Donnelly, CEO of Advarra. “Their organizational culture and values are the perfect complement to Advarra’s ‘altogether better’ approach to advancing clinical research. We look forward to collaborating with Forte’s customers and team members to continue to enhance their outstanding products and services with additional investment to serve our mutual clients.”

The combined organization supports nearly 100,000 active protocol records with top academic medical centers and health systems. Forte boasts 98 percent cumulative customer retention over 19 years of operation, serving 72 percent of NCI-designated cancer centers and 70 percent of the top 50 NIH-funded research institutions in 2019. The transaction supports continued growth for both businesses, as Advarra offers the greatest institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.

“We’re extremely proud of the highly collaborative customer community we have built over the last 19 years, which has resulted in a site-centric, integrated suite of industry-leading standards-based products and services,” said Shree Kalluri, CEO and Founder of Forte. “Joining Advarra is a great win for the research community and provides an outstanding platform for an interconnected clinical research ecosystem. Together we can transform clinical research and impact patients’ lives through the combination of eClinical technology solutions and research compliance and human subject protection services.”

“After our acquisition of Advarra in July, the Forte transaction represents a significant next step in developing, acquiring, and growing best-in-market solutions for products and services that streamline research, support faster study start-up, and enhance human research protections,” said David Golde, Managing Director of Genstar Capital. “We are excited about the value the combined organization will bring to Advarra and Forte customers.”

Forte is a portfolio company of Primus Capital. Ropes & Gray served as legal counsel to Advarra. Baird served as exclusive financial advisor and Goodwin Proctor LLP served as legal counsel to Forte. The transaction is expected to close later in September.

About Advarra

Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. Its robust regulatory expertise and innovative technology ensure the highest standards of research review are met, while putting participants first and meeting complex human research protection oversight requirements. Advarra supports all phases of research across multiple therapeutic areas. For more information, visit

About Forte

Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems. With a strong belief in community, collaboration, and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research. Forte provides all research professionals complimentary blog articles, eBooks, webinars, and more to support continuous learning on industry topics. For more information, visit

About Genstar Capital

Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $17 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrial technology, and software industries. For more information on Genstar, please visit

About Primus

Capital Primus Capital is a growth-oriented private equity firm focused on investing in leading healthcare, software, and technology-enabled services companies. Primus has invested in over 130 companies, partnering with exceptional management teams to accelerate growth and create shareholder value by applying its industry knowledge, financial resources, and investment experience. For more information about Primus Capital, please visit


Contact: Chris Tofalli
Chris Tofalli Public Relations